Latest papers

Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials.

Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials.

The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009.

Osteoarthritis: can anti-cytokine therapy play a role in treatment?

Evidence to support the therapeutic potential of bacteriophage Kpn5 in burn wound infection caused by Klebsiella pneumoniae in BALB/c mice.

Cancer and inflammation: promise for biologic therapy.

The risk of infections with biologic therapies for rheumatoid arthritis.

The perioperative use of disease-modifying and biologic therapies in patients with rheumatoid arthritis undergoing elective orthopedic surgery.

New and future agents in the treatment of rheumatoid arthritis.

Possible role of engraftment syndrome and autologous graft-versus-host disease in myelodysplastic syndrome after autologous stem cell transplantations: retrospective analysis and review of the literature.

Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.

BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy.

Company profile: Biocompatibles International plc: local drug delivery for targeted therapies.

Local dressings for pressure ulcers: what is the best tool to apply in primary and second care?

Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy.

Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy.

Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy.

Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy.

Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy.

Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy.